OPTN - Optinose Inc Stock Price, Fair Value and News

$9.17+0.01 (+0.11%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OPTN Price Action

Last 7 days

1.3%

Last 30 days

58.1%

Last 90 days

43.7%

Trailing 12 Months

-40.1%

OPTN RSI Chart

OPTN Valuation

Market Cap

92.4M

Price/Earnings (Trailing)

-4.29

Price/Sales (Trailing)

1.18

Price/Free Cashflow

-2.06

OPTN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OPTN Fundamentals

OPTN Revenue

Revenue (TTM)

78.2M

Rev. Growth (Yr)

12.86%

Rev. Growth (Qtr)

9.7%

OPTN Earnings

Earnings (TTM)

-21.5M

Earnings Growth (Yr)

96.39%

Earnings Growth (Qtr)

-177.09%

OPTN Profitability

Return on Equity

53.37%

Return on Assets

-16.73%

Free Cashflow Yield

-48.45%

OPTN Investor Care

Shares Dilution (1Y)

34.12%

Diluted EPS (TTM)

-2.04

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	74.0M	75.1M	75.7M	78.2M
2023	73.4M	72.2M	72.0M	71.0M
2022	77.5M	79.7M	77.9M	76.3M
2021	54.0M	62.1M	68.5M	74.7M
2020	40.3M	35.5M	38.6M	49.1M
2019	10.7M	16.1M	29.2M	39.9M
2018	31.3M	23.2M	15.2M	7.1M
2017	0	0	0	39.4M
2016	0	0	0	47.5M
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Optinose Inc

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

CEO	Dr. Ramy A. Mahmoud M.D., M.P.H.
WEBSITE	optinose.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	141

Optinose Inc Frequently Asked Questions

What is the ticker symbol for Optinose Inc? What does OPTN stand for in stocks?

OPTN is the stock ticker symbol of Optinose Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Optinose Inc (OPTN)?

As of Thu Apr 17 2025, market cap of Optinose Inc is 92.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPTN stock?

You can check OPTN's fair value in chart for subscribers.

Is Optinose Inc a good stock to buy?

The fair value guage provides a quick view whether OPTN is over valued or under valued. Whether Optinose Inc is cheap or expensive depends on the assumptions which impact Optinose Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPTN.

What is Optinose Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 17 2025, OPTN's PE ratio (Price to Earnings) is -4.29 and Price to Sales (PS) ratio is 1.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPTN PE ratio will change depending on the future growth rate expectations of investors.